Hutchison China MediTech Ltd. reported a loss of $26.7 million, or 43 cents per share, for 2017.
Revenues totaled $241.2 million, up from $216.1 million a year earlier.
The Hong Kong-based biopharmaceutical company, which had reported a 2016 profit of $11.7 million, or 20 cents per share, expects its losses to persist in 2018.
Chi-Med expects a net loss of between $19 million and $52 million in 2018, higher than the previous forecast of $13 million to $28 million.
